NL-OMON41970已完成2 期
A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study - Nivolumab in patients with progressive MPM: NivoMes
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 33 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Patients with proven malignant pleural mesothelioma, who have progressive disease after chemotherapy in first or second line.
- •* Patients with histological or cytological diagnosed malignant pleural mesothelioma and age > 18 years.
- •* Progressive disease after at least one course of chemotherapy.
- •* Previous chemotherapy or experimental therapy * 4 weeks ago
- •* Medically suitable for limited surgical intervention (pleural biopsies up to limited pleurectomy).
- •* Not considered candidates for trimodality treatment (as part of a study).
- •* Measurable or evaluable disease (see tumor response assessment).
- •* Ability to understand the study and give signed informed consent prior to beginning of protocol specific procedures including the approval of a second thoracoscopy or transthoracic pleural biopsy after the third course.
- •* Radiotherapy is allowed when this is given for palliation of painful sites, the interval is > 12 weeks and not all tumor is within the irradiation field.
- •* WHO performance status 0 or 1 (see appendix 1).
- •* Adequate organ function as evidenced by the following peripheral blood counts or serum chemistries at study entry:
- •* Hematology: Neutrophil count * 1.5 x 109/l, Platelets * 150 x 109/l, Hemoglobin * 6,0 mmol/l.
- •* Chemistry: Total serum bilirubin * 1.5 times within the upper limits of normal (ULN); ASAT and ALAT * 2.5 x ULN, AP (alkaline phosphatases) < 5x ULN (unless bone metastases are present in the absence of any liver disease).
- •* Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception to avoid pregnancy during treatment and for 23 weeks after the last dose of investigational drug.
- •* Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the first startdose of nivolumab.
- •* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during treatment and for a period of 31 weeks after the last dose of investigational drug.
- •* Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception.
排除标准
- •* Active uncontrolled infection, severe cardiac dysfunction or uncorrectable bleeding tendency.
- •* Inability to perform biopsies of the pleural lesions.
- •* Symptomatic peripheral neuropathy * grade 2 according to NCI CTC, version 4.0.
- •* Presence of symptomatic CNS metastases.
- •* Unstable peptic ulcer, unstable diabetes mellitus or other serious disabling condition.
- •* Impaired renal function: creatinine clearance less than 50ml/min.
- •* Concomitant administration to any other experimental drugs under investigation.
- •* Patients are excluded if they have an active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
- •* Patients are excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immuno-suppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •* Patients are excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
研究者
相似试验
进行中（未招募）
不适用
ivolumab in patients with progressive malignant pleural mesothelioma: NivoMesA single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes StudyMedDRA version: 17.1Level: LLTClassification code 10027408Term: Mesothelioma malignant advancedSystem Organ Class: 100000004864EUCTR2014-003935-20-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
已完成
2 期
PhaseII study of Nivolumab monotherapy for patients with occupational cholangiocarcinomaOccupational-related unresectable or recurrent cholangiocarcinomaJPRN-UMIN000034931ational Cancer Center Hospital East6
已完成
2 期
A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H)Colorectal cancer, Gastric cancer, Esophageal cancer, Biliary tract cancer, Pancreatic cancer, and Other gastrointestinal cancerJPRN-UMIN000033182ational Cancer Center Hospital East70
招募中
4 期
Phase II study of adjvant Nivolumab monotherapy for esophageal cancer.Esophageal cancerD004938JPRN-jRCT1031220223Yagi Koichi99
进行中（未招募）
2 期
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkerJPRN-jRCTs031180013Kagamu Hiroshi60